Business
BioVie to Host Virtual KOL Event on NE3107 in Alzheimer’s Disease on September 7, 2023
CARSON CITY, Nev., Aug. 31, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative
About this update from Biovie Inc.
[{"type":"text","content":"CARSON CITY, Nev., Aug. 31, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced it will host a virtual KOL event titled NE3107―Putting Data in Context, ahead of the upcoming Phase 3 results in Alzheimer’s Disease. The event will take place on Thursday, September 7, 2023 at 2:30pm ET. To register, click here. The event will focus on BioVie’s lead product candidate, NE3107, currently in a potentially pivotal Phase 3 study in patients with mild to moderate Alzheimer’s disease with expected topline data readout in the fourth quarter of 2023. The company’s leadership team and Key Opinion Leader (KOL) Steven E. Arnold, MD (Harvard Medical School; Massachusetts General Hospital) will discuss the totality of NE3107 data generated to date including: Overview of results observed in the NE3107 Phase 2 exploratory biomarker study.The role of neuroinflammation and insulin resistance in Alzheimer’s Disease pathology.The potential for NE3107 to have an active epigenetic effect associated with improvements in inflammation, insulin signaling, and other critical biological processes in a manner that is significantly correlated to improvements in cognition. A live question and answer session will follow the formal presentations. About Steven E. Arnold, MDAfter receiving his MD from Boston University, Dr. Arnold completed residency training in Psychiatry at the New York State Psychiatric Institute / Columbia Presbyterian Medical Center in New York, residency training in Neurology and fellowship training in Behavioral Neurology at the University of Iowa Hospitals and Clinics in Iowa City. Dr. Arnold is board certified in both neurology and psychiatry. At the Massachusetts General Hospital, Dr. Arnold leads the Alzheimer's Clinical and Translational Research Unit, conducting early phase clinical trial and biomarker research. He is also Managing Director of the Interdisciplinary Brain Center, a new collaboration of the Departments of Neurology, Psychiatry and Radiology. Its mission is to facilitate the discovery, development, and implementation of promising therapeutics and associated diagnostics for individuals with complex brain disorders affecting co...